UTMD

Business Context and Reporting Period

Company: Utah Medical Products Inc. (UTMD)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: UTMD designs, manufactures, and distributes specialized medical devices for critical care, labor and delivery, neonatal intensive care, and gynecology. The company operates manufacturing facilities in Utah and Ireland, with distribution subsidiaries in the UK, Canada, and Australia. Key products include the Filshie Clip System (female sterilization), INTRAN PLUS (fetal monitoring), and various neonatal catheters and respiratory hoods.

Key Financial Metrics (Year Ended Dec 31, 2025)

Material Changes vs. Prior Period

• Revenue Decline (-5.8%): Driven primarily by the cessation of sales to a major OEM customer (PendoTECH), which dropped from $2.7 million in 2024 to $0.4 million in 2025. Additionally, a key China distributor for blood pressure monitoring kits canceled a committed order, resulting in a $0.3 million revenue shortfall and a $0.4 million bad debt write-off.
• Margin Compression: Gross margin decreased 1.9 percentage points due to fixed overhead costs remaining high despite lower sales volume, increased raw material costs, and tariffs. Operating income margin fell from 33.2% to 29.6%.
• Unusual Expenses: General and Administrative (G&A) expenses included a $0.395 million write-off for the China distributor cancellation fee and a $0.195 million loss due to embezzlement by a former Australia subsidiary manager.
• Legal Costs: Litigation expenses related to Filshie Clip System lawsuits decreased by $0.78 million to $1.36 million, as 15 of 19 active cases were dismissed as of March 2026.
• Shareholder Returns: The company repurchased 148,935 shares for $8.36 million and paid $3.98 million in dividends, returning 109% of net income to shareholders.

Guidance, Outlook, and Risks

• 2026 Outlook: Management projects consolidated sales to remain flat compared to 2025, as losses from PendoTECH and the China distributor are expected to be offset by new product sales and organic growth. Operating income is projected to increase 15-18% in 2026, driven by the full amortization of Femcare identifiable intangible assets (saving ~$1.6 million in G&A) and potential gross margin expansion.
• EPS Target: Management estimates 2026 diluted EPS will exceed $4.00 per share.
• Key Risks:
  • Product Liability Litigation: Ongoing lawsuits regarding Filshie Clip migration. While 15 of 19 cases have been dismissed, remaining cases in Connecticut state court pose uncertainty. Management believes costs will not be material.
  • Trade Policy: Reciprocal tariffs and U.S. trade policies have negatively impacted OUS sales and increased costs. The company plans to shift some manufacturing to Ireland to mitigate U.S. income tax impacts.
  • Customer Concentration: Reliance on third-party distributors and OEMs creates revenue volatility, as evidenced by the PendoTECH and China distributor exits.

Investor Verification Checklist

• Revenue Replacement: Verify the progress of new biopharmaceutical transducer sales and other organic growth initiatives intended to replace the $2.5 million in lost OEM and China distributor revenue.
• Litigation Status: Monitor the status of the remaining Filshie Clip lawsuits in Connecticut state court and any potential trial dates or settlement discussions.
• Intangible Asset Amortization: Confirm the cessation of the ~$2.1 million annual Femcare identifiable intangible asset amortization expense in Q1 2026 as a driver for margin improvement.
• FX Exposure: Assess the impact of foreign currency fluctuations (EUR, GBP, AUD, CAD) on reported USD revenues and expenses, given that 72% of OUS sales are invoiced in foreign currencies.
• Internal Controls: Review the company's response to the embezzlement incident in Australia to ensure robust internal controls are in place to prevent recurrence.